Financial Gravity Asset Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
BCM
AIM
Financial Gravity Asset Management's TXG Position: Q3 2023 in Review
Financial Gravity Asset Management sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 56 shares — an estimated $45 sold.
Financial Gravity Asset Management first reported a position in TXG in Q4 2022 and held it in 2 quarters. The position peaked at $45 in Q2 2023. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.
- Financial Gravity Asset Management reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
- Financial Gravity Asset Management sold 56 10x Genomics shares in Q3 2023, an estimated $45.
- Financial Gravity Asset Management first reported a position in 10x Genomics in Q4 2022 and held it in 2 quarters.
- Financial Gravity Asset Management's 10x Genomics position peaked at $45 in Q2 2023.
- 256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.
Based on Financial Gravity Asset Management's 13F filing for Q3 2023, filed 16 Nov 2023.